TG Therapeutics Posts 71% Increase in Briumvi Sales

By Bobby Samwell • Monday, August 03 10:56 • Permanent Link

TG Therapeutics posted a sharp jump in Briumvi sales in the second quarter and lifted its full-year revenue outlook.

Second-quarter 2026 total global revenue reached $240.3 million, up from $140.9 million in the same quarter a year earlier. Briumvi U.S. net product revenue accounted for $227.7 million of that total, rising 64% from the prior-year period.

For the first half of 2026, product revenue climbed to $437.1 million from $258.5 million a year earlier. U.S. Briumvi net product revenue for the six months was $422.5 million, compared with $248.7 million in the first half of 2025.

The company raised its full-year 2026 total global revenue target to about $950 million, from its prior outlook implied by earlier guidance, and increased its Briumvi U.S. net product revenue target to $890 million to $905 million.

Revenue growth came alongside higher spending. Research and development expense rose to $95.3 million in the second quarter from $31.8 million a year earlier, while selling, general and administrative expense increased to $82.1 million from $55.6 million. For the first six months, R&D climbed to $143.7 million from $78.1 million, and SG&A rose to $170.3 million from $105.9 million.

Net income fell to $7.8 million in the second quarter from $28.2 million a year ago. For the first half, net income was $27.6 million, down from $33.2 million.

The company ended June with $612.3 million in cash, cash equivalents and investment securities. Following these announcements, the company's shares moved -9.05%, and are now trading at a price of $47.32. For more information, read the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.